Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker BEFREE Modulator of the PI3K/Akt oncogenic pathway affects mTOR complex 2 in human adenocarcinoma cells. 30542835

2019

Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker BEFREE KRAS and EGFR mutations were significantly more frequent in adenocarcinomas: PIK3CA in squamous cell carcinomas. 29186353

2018

Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 AlteredExpression BEFREE Moreover, the non-adenocarcinoma (SCLC) component might arise from the adenocarcinoma (NSCLC) component through a mechanism that involves the activation of the ASCL1 and PI3K/AKT1 signaling pathways. 30429033

2018

Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker BEFREE Recent experiments have shown that in adenocarcinoma, K-Ras4B is involved in the CaM-PI3Kα crosstalk. 29300353

2018

Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 GeneticVariation BEFREE In squamous cell carcinomas more often multiple mutations per sample (p=0.040), and more PIK3CA (p=0.039) and CTNNB1 (p=0.038) mutations were detected compared to adenocarcinomas. 29113722

2018

Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 GeneticVariation BEFREE Here we report measurements of PIK3CA H1047R mutant fraction (MF) in normal colonic mucosa, normal lung, colonic adenomas, colonic adenocarcinomas, and lung adenocarcinomas. 28755461

2017

Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 AlteredExpression BEFREE The activated pathway in lung ADC and SCC mainly focuses on MAPK and PI3K with different key genes of each, respectively, and the activated pathway of SCLC mainly focuses on JAK-STAT pathway. 27845189

2017

Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 GeneticVariation BEFREE Patient harboring a novel PIK3CA point mutation after acquired resistance to crizotinib in an adenocarcinoma with ROS1 rearrangement: A case report and literature review. 28845578

2017

Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 GeneticVariation BEFREE KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior. 28188750

2017

Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 GeneticVariation BEFREE Low incidence of KRAS, BRAF, and PIK3CA mutations in adenocarcinomas of the ampulla of Vater and their prognostic value. 26997442

2016

Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 GeneticVariation BEFREE GAs in the PI3K/AKT/mTOR pathway were more common in SDC (53.6%) than other histologies (P = 0.019) Cyclin-dependent kinase GAs varied among all histotypes: adenocarcinoma, NOS (34.6%); SDC (12.2%); ca ex PA (16.7%); carcinoma, NOS (31.2%; P = 0.043). 27334835

2016

Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 GeneticVariation BEFREE Of 24 patients with actionable mutations, five were given genotype-matched drugs corresponding to actionable mutations: everolimus to PIK3CA mutation in parotid carcinosarcoma (partial response) and tracheal squamous cell carcinoma (stable disease; 21% reduction), sorafenib to PDGFRA mutation in auditory canal adenocarcinoma (partial response), sorafenib to BRAF mutation in microcytic adnexal carcinoma (progressive disease), and afatinib to ERBB2 mutation in esophageal adenocarcinoma (progressive disease). 27105424

2016

Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker BEFREE Synchronous lung cancers from 60 patients (42 with adenocarcinoma and 18 with squamous cell carcinoma), clinically considered to represent intrapulmonary metastases, were histologically subtyped according to the 2015 World Health Organization classification of lung tumors and subjected to genotypic analysis (KRAS, EGFR, BRAF, PIK3CA, ALK, MET and ROS1 in adenocarcinoma and PIK3CA and p16 in squamous cell carcinoma). 27080983

2016

Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 GeneticVariation BEFREE However, an unpublished mutation of the PIK3CA gene in exon 20 (W1051 stop mutation) was found in one case of adenocarcinoma NOS. 26811072

2016

Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 GeneticVariation BEFREE PIK3CA mutations occurred more frequently in SCC than AC (25% vs. 11%, P=0.025), whereas KRAS mutations occurred more frequently in AC than SCC (24% vs. 3%, P<0.001) and ASC (24% vs. 3%, P<0.001). 26197069

2015

Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker BEFREE We hypothesize that calmodulin recruits and helps activate PI3Kα at the membrane, and that this is the likely reason for Ca(2+)/calmodulin dependence in adenocarcinomas. 26085527

2015

Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker BEFREE CHFR expression, analyzed by RNA-seq, was classified as high vs. low based on the median CHFR expression level and correlated with the presence or absence of lung cancer specific mutations (EGFR, KRAS, ALK, MET, ERBB2, TP53, STK11, ROS1, RET, NF1, Pik3CA for adenocarcinomas and FGFR1, FGFR2, FGFR3, TP53, STK11, EGFR for squamous cell carcinomas). 25477232

2015

Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 GeneticVariation BEFREE PIK3CA-mutated NSCLC represents a clinically and genetically heterogeneous subgroup in adenocarcinomas as well as in squamous cell carcinomas with a higher prevalence of these mutations in sqamous cell carcinoma. 25473901

2015

Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 GeneticVariation BEFREE When analyzing all PI3K pathway components together, we show that patients with at least one alteration in the PI3K pathway are twice as likely to have SCC, than ADCA. 24500884

2014

Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 GeneticVariation BEFREE Single nucleotide substitutions in TP53 and PIK3CA genes were detected in 36% and 11% of adenocarcinoma, in 16% and in 5% of squamous cell carcinoma, and in 13% and none of CIN 3, respectively. 25220666

2014

Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 GeneticVariation BEFREE PIK3CA mutation was found in 3.9% of squamous cell carcinoma and 2.7% of adenocarcinoma. 24533074

2014

Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 GeneticVariation BEFREE Patients with adenocarcinoma had fewer PIK3CA mutations (14%), and survived longer (median, 14.2 months) than those with squamous cell carcinoma (48% and 7.2 months; p = 0.016, and 0.001, respectively). 25426553

2014

Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker BEFREE In highly differentiated adenocarcinomas the ErbB2/ErbB3 complex is activated, which is followed by phosphatidylinositol 3-kinase (PI3K) activation. p38 MAP kinase is activated downstream of PI3K and adherens junctions are disrupted via Rac1 activation. 25019985

2014

Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 GeneticVariation BEFREE PIK3CA mutation rates did not differ significantly between adenocarcinomas and squamous cell carcinomas (25% vs 37.5%, respectively; P = .33). 24037752

2013

Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
CUI: C0001418
Disease: Adenocarcinoma
Adenocarcinoma
0.400 Biomarker BEFREE The most prevalent biomarkers in pulmonary adenocarcinoma were KRAS mutations (29%), loss of PTEN expression (18%), EGFR mutations (9%), HER2 amplification (5%) and BRAF mutations (3%), while the prevalence of ALK translocations and PIK3CA mutations was extremely low. 23876834

2013